What patients and customers should know?
Currently, the most vital information for the prospective patient or customer of the medication Biktarvy
is that the price of medication in India will drop shortly.
As many people may already know, the manufacturer Gilead Sciences, based in USA, has priced the original medicine at US$3583 for a pack of 30 tablets. Mexico, which in fact imports the generic copy from India, prices the same package at $531.
But India, which has been authorized to produce the generic version by Gilead Sciences, has priced the
same package at only $150 for Biktarvy cost. Which is amazing and a great deal, when you really think about it.
That is a real fraction of the original market value.
I have explained in previous documents that the generic copy is made without research and
development (R&D), which adds to the cost of manufacturing considerably. Gilead Sciences certainlyadds the total cost in this way.
Since the generic is a copy. It can be made without that and the cost will be relatively cheaper in comparison, which makes it a more available and popular prescription.
India, which is known for medical professionalism as well, has produced a global impact due to its
accessibility of affordable, generic drugs and medicines.
That includes HIV preventative and treatment drugs like Biktarvy.
The impact around the world is that India’s market has caused sellers and distributors in other countries to reduce prices, doubtlessly for competition. Mexico is one of them.
Biktarvy is a combined medication prescribed for HIV [Herpes Immunodeficiency Virus], which is common around the world.
It has the following active ingredients, listed with relative strengths:
bictegravir (50mg), emtricitabine (200mg) and tenofovir alefeminide (25mg).
Its effectiveness and efficacy with HIV have termed it “highly active antiretroviral therapy”.
Anyone seeking additional information regarding this topic should research through the following
publications about India:
1. Journal of Law, Medicine & Ethics [article: India’s Generic Drug Industry and the Global
HIV/AIDS Pandemic”]
2. The Atlantic [article: ”How India’s Generic Drug Industry is Helping to Fight HIV/AIDS in the
Developing World”]
3. Journal of Generic Medicines [article: India’s Generic Drug Industry and its Role in Providing
Affordable HIV/AIDS Medications”]
4. New England Journal of Medicine [article: “The Role of India in Making HIV/AIDS Treatment
More Affordable”] and
5. Journal of Global Health [article: “India’s Generic Drug Industry and Impact on Global Health”]